Search Results

To assist a current or future law student who has been affected by leukemia or lymphoma by helping to defray the cost of law school expenses.

Offers an annual scholarship of $1,000 for law school tuition and/or books
Applicant must submit an essay and complete online application
Check website for additional eligibility criteria and rules.

Students affected by leukemia or lymphoma and interested in pursuing a law degree in the US

Website http://www.renkinlaw.com/leukemia-lymphoma-law-school-scholarship/

Spotlight on Aggressive Non-Hodgkin Lymphomas (NHL)

Genetic Study of Familial Chronic Lymphocytic Lymphoma

To increase understanding of the causes of lymphoma and to learn more about the genes that contribute to the disease.

The study is based at Dana-Farber Cancer Institute in Boston, Massachusetts

Families with at least 2 first-degree relatives (parent, sibling or child) with lymphoma such as Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma.

Website http://www.dana-farber.org/center-for-chronic-lymphocytic-leukemia/clinical-res…

Treating Indolent Lymphoma: Common and Rare Types

Advancements in Aggressive Non-Hodgkin Lymphomas (NHL)

On World Cancer Day: LLS Honors International Researchers

World Cancer Day is February 4, when people across the globe come together to work toward reducing the global burden of cancer. An integral part of this work is scientific research that leads to innovative treatments, ultimately saving lives.

Despite promising advances in treatment, cancers are among the leading cause of disease and deaths worldwide. Cancers know no boundaries, and have devastating impacts on families across the globe.

Raising Our Voices

LLS Partner Advances Promising Therapy for Rare Leukemia

A potential new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a very rare form of blood cancer with no standard treatment, continues to show promise as it moves through early clinical trials. The Leukemia & Lymphoma Society (LLS) has a long history of supporting the development of SL-401, a targeted therapy that has shown significant anti-tumor effects.

A scientist stands above a petri dish with a dropper and places a liquid solution on the dish.

The Immune System and Blood Cancer: 4 Things You Need to Know

Immunotherapy uses the power of the immune system to treat blood cancer. Today it is a standard treatment that has a profound effect in some blood cancer patients, but it still falls short in others.

The Leukemia & Lymphoma Society (LLS) has been a champion of this type of cancer treatment for decades, supporting some of the earliest and most game-changing immune-based treatments for blood cancer. The advances have been astonishing, but there is so much further to go.

HIGH SCHOOL STUDENTS 'TEST' THE LIMITS OF PHILANTHROPY

For the second year in a row, high school students across the country are redefining what it means to be philanthropic in today’s youth culture. Through The Leukemia & Lymphoma Society’s (LLS) newest innovation in fundraising, Students of the Year, more than 600 motivated high school students raised significant funds for LLS’s cutting-edge cancer research and patient services.

Relevance of ubiquitin dependent proteolysis in Diffuse Large B-cell lymphoma

The goal of this proposal is to investigate the significance of genes of the ubiquitin proteasome system (UPS) that are mutated in Diffuse Large B-cell Lymphoma (DLBCL). Our studies leverage the expertise in the molecular modeling of the UPS in the pathogenesis of DLBCL utilizing mouse models, patient derived xenotransplant (PDX) and cell lines. Our goal is the understanding of how genetic mutations contribute to disease development, progression and therapeutic outcome.

Clinical investigation to improve efficacy of CAR-T Cell Therapy for Large B Cell Lymphoma

We are investigating new interventions that could improve the effectiveness of CAR T-cell therapy for lymphoma. A clinical trial will test radiation immediately followed by CAR-T. Larger lymphoma tumors are less likely to respond to CAR-T and we expect that radiation could reduce the amount of tumor, leading to improvement in responses. We will also conduct a series of trials to determine the effectiveness of vaccinations before and after CAR T cell therapy, and if anti-cancer vaccines could improve outcomes.

Romidepsin

Romidepsin is FDA approved for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least one prior systemic therapy and treatment of patients with peripheral T-cell lymphoma (PTCL) who have received at least one prior therapy.

Chlorambucil

Chlorambucil is FDA approved to treat people who have chronic lymphocytic leukemia (CLL), some types of non-Hodgkin lymphoma and advanced Hodgkin lymphoma.

Tafasitamab-cxix

Tafasitamab-cxix is approved in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Molecular Pathogenesis and Therapeutic Targets for Transformed Marginal Zone and BN2 Lymphomas

This project is the first to explore the origin of a newly discovered type of lymphoma called “BN2-DLBCL”. Mutations in a gene called “SPEN” are a defining feature of these tumors. Strikingly, SPEN mutations are more common in females and cause more deadly disease. Our proposal will reveal for the first time how these tumors originate from the immune system, how they are intimately linked to autoimmune disorders such as Lupus, why they occur preferentially in women, and how to cure them.  

Defining and Redefining a Blood Cancer Diagnosis

Science historian June Goodfield wrote, “Cancer begins and ends with people.”

This Blood Cancer Awareness Month, it’s important to know that The Leukemia & Lymphoma Society (LLS) is on a mission to cure blood cancers and improve quality of life for the nearly 1.7 million people in the U.S. living with or in remission from blood cancer.

LLS is all about people—an organization full of people who are united in the urgent effort to help every person impacted by blood cancer.

Clinical Trials: Why They Matter and How to Make Them More Accessible

Cancer treatments can be lifesaving. As an organization, The Leukemia & Lymphoma Society (LLS) has invested more than $1.7 billion in blood cancer research since its inception in 1949—all with the hope that this research leads to scientific breakthroughs that improve and save lives.

But to make sure this research leads to safe and innovative treatments, we have to thoroughly test it.

Meet The Researcher: Dr. Rayne Rouce

Researchers Share Key Career Advice with LLS College Club Members

I recently had the privilege of moderating an LLS on Campus Researcher Panel attended by LLS college club members from nearly 30 universities across the country. These clubs bring together students interested in pursuing health-related careers and provide opportunities to hear from scientists working to better understand and treat blood cancers.

What’s Next in Blood Cancer: Looking Ahead to 2023

The most important blood cancer scientific meeting, the American Society of Hematology (ASH), is held every December.